Mild to Moderate Acne | Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne
Mild to Moderate Acne research study
What is the primary objective of this study?
This is a clinical trial to compare the benefits and possible adverse events of two antibiotic treatments for mild to moderate acne. It is expected that minocycline microgranules will be more effective than lymecycline with a better adverse events profile.
Who is eligible to participate?
Inclusion Criteria: - Both gender - 14 to 30 years old - Mild to moderate acne - Face localization - At least 20 non-inflammatory lesions OR - At least 15 inflammatory lesions OR - At least 30 total lesions AND - Less than 5 nodular lesions Exclusion Criteria: - Patients younger than 14 or older than 30 years old - Less than 20 non-inflammatory lesions OR - Less than 15 inflammatory lesions OR - Less than 30 total lesions - Patients with severe acne - More than 5 nodular lesions OR - More than 50 inflammatory lesions OR - More than 125 total lesions - Pregnant women - Lactating women
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Mild to Moderate Acne
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Minocycline vs LymecyclineMinocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Minocycline 100 mgMinocycline
Lymecycline 300 mgGroup B: Lymecycline
Start Date: June 2009
Completed Date: April 2010
Phase: Phase 4
Primary Outcome: Number of inflammatory and non-inflammatory acne lesions
Secondary Outcome: Incidence of local and systemic adverse events
Study sponsors, principal investigator, and references
Lead Sponsor: Darier